- Company to Highlight Significant and Expanding Commitment to the Treatment
of Urological Diseases -
CORONA, Calif., May 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today
that management will host and webcast a meeting for the investment community
at the American Urological Association (AUA) Annual Meeting taking place in
Orlando, Florida May 17-22, 2008.
The company will be hosting the meeting to provide an overview of its
Brand business and to review data presented on two new studies:
-- The cardiovascular rhythm effects of silodosin vs. a placebo and a
positive control arm in patients with benign prostatic hyperplasia
(BPH) -- or enlargement of the prostate
-- Efficacy and tolerability of oxybutynin topical gel vs oxybutynin
patch in patients with overactive bladder
The event will be held on Tuesday May 20, 2008 from 3:30 p.m. to 5:00 p.m.
Eastern Daylight Time at The Peabody Orlando Hotel, 9801 International Drive,
Mezzanine Level, Bayhill Suite 2, Orlando, FL. To participate in the event in
person, please RSVP to Patty Eisenhaur, Executive Director, Investor Relations
by Friday, May 16th at 951.493.5611.
The presentation will be webcast live and can be accessed on Watson
Pharmaceuticals' Investor Relations Web site at http://ir.watson.com or at
eventDetails&c=65778&eventID=1848531. Pre-registration is not required to
view the webcast. An archived version will be available for 30 days after the
live presentation and can be accessed at the same location.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc, headquartered in Corona, California, is a
leading specialty pharmaceutical company that develops, manufactures, markets,
sells and distributes brand and generic pharmaceutical products. Watson
pursues a growth strategy combining internal product development, strategic
alliances and collaborations and synergistic acquisitions of products and
For press releases and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watson.com.
SOURCE Watson Pharmaceuticals, Inc.
CONTACT: Patty Eisenhaur of Watson Pharmaceuticals, Inc.,
Web site: http://www.watson.com